Skip to main content

ACoP 2024 Main banner

Conference Program

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

S
T-114
SAS Macro for Validation of NONMEM Data Items Pertaining to Implicit Expansion of Dose Records in Oral Dose Population Pharmacokinetic Datasets

Favorite
W-031
Scientific Project Management (SPM) to Enhance Model-Informed Drug Development

Favorite
M-117
Semi-mechanistic modeling to investigate differential dynamics of anti-citrullinated protein antibody (ACPA) IgG versus total IgG reduction following nipocalimab treatment

Favorite
W-062
SEMI-PHYSIOLOGIC POPULATION PHARMACOKINETIC MODEL TO EVALUATE THE EFFECT OF HEPATIC-UPTAKE TRANSPORTER GENE SLC22A1 POLYMORPHISM ON PHARMACOKINETICS OF PROGUANIL AND ITS METABOLITE, CYCLOGUANIL

Favorite
T-021
Semi-physiological population pharmacokinetic (PPK) model using dose optimization data for ASTX030, an oral fixed-dose combination (FDC) of CDA inhibitor cedazuridine and azacitidine in MDS patients

Favorite
M-105
Sex differences in patients with chronic kidney disease: A quantitative systems pharmacology modeling study

Favorite
T-019
Simulate modified Nonmem models using NMsim

Favorite
T-106
Simulated CD8+ T Cell-Mediated Liver Injury During Ipilimumab Administration in a Simulated Population (SimPops®) Demonstrates Profiles Consistent with Observed Clinical Data

Favorite
W-007
Simulating Adaptive Dosing Regimens from PK and PKPD Models Using mrgsolve

Favorite
T-110
Simulation of Trial Predictions with Model Uncertainty using NMsim

Favorite
W-022
Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease

Favorite
W-116
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

Favorite
W-024
Small molecule exposure prediction (intravenous (IV) and oral (PO)) using Machine learning (ML) in combination with mechanistic modeling.

Favorite
M-067
Stochastic Simulation and Estimation (SSE) for Design of Sample Size and Time Points in Pediatric Studies

Favorite
M-123
Streamlining Dupilumab Nasal Polyposis Clinical Development Strategy: Leveraging Modeling and Biomarker Bridging for the Phase 3 Dose Selection

Favorite
M-062
Successful Dose Optimization and Recommended Phase III Dose Determination of Saruparib (PARP1 Selective Inhibitor) Through MIDD and Comprehensive Quantitative Clinical Pharmacology

Favorite
T-127
Surface plasmon resonance enabled mechanistic pharmacokinetic/pharmacodynamic modeling to support covalent inhibitor drug development: Bruton’s tyrosine kinase inhibitor case study

Favorite
T-039
Symbolic PBPK-PDE Modeling Using Open-Source Julia Tools

Favorite
W-035
Systems model to predict fractional exhaled nitric oxide response to inhaled JAK inhibitors in patients with mild to moderate asthma

Favorite